Parameter
| Biomarker | Faecalibacterium prausnitzii | Full name | Faecalibacterium prausnitzii | Molecular Type | Bacteria (Firmicutes) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Monitoring of gut microbiota homeostasis | ||
| Disease | Inflammatory Bowel Disease (IBD) | Disease Subtypes | / | ||
| Organ | Intestine | Test Sample / Technology Platform | Stool (16S rRNA sequencing, qPCR, metagenomic sequencing, and fluorescence in situ hybridization) | ||
| Pathobiological Mechanisms | (1) The main butyric acid-producing bacteria in the gut inhibit HDAC1 activity by producing butyric acid, down-regulate the NF-κB pathway, and reduce the release of IL-6 and TNF-α; (2) Significantly decreased abundance in IBD patients (decreased by 60% in CD patients and 45% in UC patients), leading to insufficient energy supply and impaired barrier repair capacity of intestinal mucosa; (3) Abundance is positively correlated with mucosal healing rate, and low abundance (< 1% of total gut microbiota) indicates a 2.5-fold increased risk of IBD recurrence | ||||
| Clinical Availability Status | Clinical Research Applications | ||||
| Notes and Dynamics | 1. When the abundance ratio of F. prausnitzii to E. coli > 0.8, the response rate of anti-TNF therapy in CD patients increased by 40% (Gut study, 2025); (2) The phase Ⅲ clinical trial (NCT05789214) of a probiotic formulation containing F. prausnitzii for remission maintenance in UC has been enrolled, and the preliminary results show that the remission rate increased by 28% | ||||